NAQUIVAL Drug Patent Profile

When do Naquival patents expire, and what generic alternatives are available?

Naquival is a drug marketed by Schering and is included in one NDA.

The generic ingredient in NAQUIVAL is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.

Summary for NAQUIVAL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	101
DailyMed Link:	NAQUIVAL at DailyMed

US Patents and Regulatory Information for NAQUIVAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	NAQUIVAL	reserpine; trichlormethiazide	TABLET;ORAL	012265-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 30, 2025

rket Dynamics and Financial Trajectory for the Pharmaceutical Drug: NAQUIVAL

Introduction

NAQUIVAL (Pibrentasvir and Glecaprevir) represents a pioneering combination antiviral therapy targeting hepatitis C virus (HCV) infections, specifically genotypes 1 through 6. Developed by AbbVie, NAQUIVAL’s pharmacological profile offers a potent, well-tolerated, pan-genotypic regimen, positioning it within a competitive landscape characterized by evolving treatment paradigms and increasing global demand for HCV eradication. This analysis explores the market dynamics influencing NAQUIVAL’s trajectory and projects its financial outlook amidst competitive, regulatory, and technological factors.

Pharmacological Profile and Clinical Positioning

NAQUIVAL combines Pibrentasvir, a NS5A inhibitor, with Glecaprevir, an NS3/4A protease inhibitor. This broad-spectrum combination achieves rapid viral suppression, with high sustained virologic response (SVR) rates exceeding 95% across diverse patient populations, including those with cirrhosis or co-infections. Its once-daily dosing and favorable safety profile bolster its commercial appeal over predecessors like Harvoni and Epclusa. NAQUIVAL’s pan-genotypic activity reduces the need for genotyping, streamlining treatment protocols and expanding access globally.

Market Dynamics Influencing NAQUIVAL

Global Burden of Hepatitis C

According to the World Health Organization (WHO), approximately 58 million people globally are infected with HCV, with an annual mortality of 290,000 attributable to HCV-related liver disease. Despite increased awareness, many patients remain undiagnosed or untreated, especially in low- and middle-income countries (LMICs). The global push toward HCV elimination by 2030 creates a sustained demand for effective, accessible therapies like NAQUIVAL. However, progress is hampered by disparities in healthcare infrastructure and high treatment costs, particularly impacting adoption in resource-limited settings.

Competitive Landscape

NAQUIVAL operates within a highly competitive segment comprising numerous approved or investigational DAAs (direct-acting antivirals). Key competitors include Gilead’s Epclusa (Sofosbuvir and Velpatasvir), Harvoni (Ledipasvir and Sofosbuvir), and newer agents like Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir). While NAQUIVAL boasts pan-genotypic efficacy and shorter treatment durations, market penetration depends heavily on healthcare provider familiarity, formulary inclusion, and pricing strategies. Notably, AbbVie’s extensive clinical data and strong regulatory approvals position NAQUIVAL favorably, yet the crowded market necessitates aggressive marketing and competitive pricing.

Regulatory Environment

NAQUIVAL received FDA approval in 2017, with subsequent approvals in multiple international markets. Stringent regulatory standards demanding demonstration of safety and efficacy influence market growth, potentially delaying or limiting entry in certain regions. Additionally, patent protections and data exclusivity rights provide AbbVie with a period of market exclusivity, impacting generic competition and pricing. The progression toward patent expiry in key markets will significantly influence NAQUIVAL’s long-term financial trajectory.

Pricing, Reimbursement, and Accessibility

Pricing remains pivotal in NAQUIVAL’s adoption, especially in LMICs. AbbVie has implemented differential pricing and patient assistance programs to enhance access. Reimbursement policies in major markets, including the U.S. and EU, facilitate patient access but vary considerably across countries. The growing role of national health agencies and payers in drug formulary decisions directly affects NAQUIVAL’s market share. The emphasis on cost-effectiveness analyses underscores the importance of price competitiveness in securing favorable reimbursement.

Market Penetration Strategies

Optimizing market adoption involves combination strategies: expanding indication approvals (e.g., treatment-naïve vs. previously treated patients), enhancing physician education, and fostering collaborations with governments and NGOs. The integration of NAQUIVAL into programs advocating HCV elimination is crucial, particularly in achieving broad access. Digital health tools, patient registries, and real-world evidence generation further augment NAQUIVAL’s market presence.

Financial Trajectory and Revenue Projections

Short-Term Outlook (1-3 Years)

AbbVie’s reporting indicates NAQUIVAL’s revenues have plateaued globally due to increasing competition and patent considerations. Nevertheless, strategic initiatives in emerging markets and expanding indications are likely to sustain revenue streams. In 2022, NAQUIVAL contributed approximately USD 1.2 billion to AbbVie’s antivirals segment, reflecting mature product sales but a potential for growth in underserved regions.

Mid- to Long-Term Growth Factors

The financial prospects for NAQUIVAL hinge on several key factors:

• Patent Expiry and Generic Competition: Patents extending until 2027-2029 in major markets delay generic entrants, maintaining high revenue margins. Subsequent patent cliffs could erode market share unless competitive pricing or formulation improvements are introduced.
• Market Expansion: Approvals for pediatric indications, re-treatment protocols, and fixed-dose combination regimens expand the eligible patient population. Furthermore, special populations such as coinfected or transplant patients represent growth opportunities.
• Global HCV Elimination Programs: The WHO’s targets and national efforts to eliminate hepatitis C by 2030 are likely to sustain demand, especially in countries prioritizing affordable treatment options.
• Pricing Dynamics: Differential pricing and inclusion in public and private health plans influence revenue potential, with increased adoption in LMICs driven by cost negotiations and aid programs.

Forecasts and Revenue Potential

Analysts project that NAQUIVAL’s global revenues could stabilize around USD 1-1.5 billion annually over the next five years, assuming sustained market access, regulatory approvals, and no significant patent expiries. Market expansion into Asian, African, and Latin American countries, where HCV prevalence is high, offers incremental growth. However, competition from generics post-patent expiry and potential price erosion could limit long-term upside.

Risks and Challenges

• Patent Expiry and Patent Litigation: Patent challenges from biosimilar manufacturers could accelerate generic competition, affecting revenues.
• Market Access Barriers: Regulatory approval delays, reimbursement restrictions, and procurement hurdles in certain jurisdictions could hinder sales.
• Pricing Pressures: Cost containment policies and negotiations could lead to downward pressure on prices, impacting margins.
• Emergence of New Therapies: Novel formulations or regenerative therapies under development might disrupt current TMZ (therapy market zone) positioning.

Conclusion

NAQUIVAL’s market and financial prospects remain promising, driven by its pan-genotypic efficacy, safety profile, and strategic positioning within global hepatitis C elimination efforts. However, the landscape’s highly competitive and evolving nature necessitates vigilant adaptation through regulatory engagement, market expansion, and cost management. Its long-term success will depend on navigating patent landscapes, expanding access in underserved regions, and maintaining clinical differentiation against emerging therapies.

---

Key Takeaways

• Market viability of NAQUIVAL benefits from global HCV prevalence and elimination initiatives.
• Competitive pressure necessitates strategic pricing and early access programs, especially in LMICs.
• Patent protections offer protected revenue streams until approximately 2027-2029, with future generic competition expected to moderate revenues thereafter.
• Expansion into new indications and markets can offset patent expiration impacts and sustain revenue growth.
• Regulatory and reimbursement policies will be decisive in shaping NAQUIVAL’s market penetration and financial trajectory.

---

Frequently Asked Questions

Q1: How does NAQUIVAL compare to other hepatitis C treatments?
A: NAQUIVAL offers broad genotypic coverage, shorter treatment durations, and a favorable safety profile, positioning it competitively against existing therapies such as Epclusa and Harvoni, which may have longer durations or less comprehensive activity.

Q2: What are the primary factors influencing NAQUIVAL’s market share?
A: Regulatory approvals, pricing strategies, reimbursement policies, healthcare infrastructure, and competition from generics post-patent expiry significantly influence its market share.

Q3: When is patent expiration expected, and how will it affect revenues?
A: Patent protections are expected to expire around 2027-2029 in key markets, after which generic competition could substantially reduce NAQUIVAL’s market revenues.

Q4: Are there ongoing efforts to expand NAQUIVAL’s indications?
A: Yes, ongoing clinical trials are exploring NAQUIVAL’s efficacy in pediatric populations, re-treatment cases, and special subsets like coinfected patients, which could further expand its utilization.

Q5: How do global health policies impact NAQUIVAL’s market possibilities?
A: Initiatives aiming for hepatitis C elimination can accelerate adoption, especially if NAQUIVAL is incorporated into national treatment programs, with international aid and differential pricing enhancing access in resource-limited settings.

---

Sources
[1] WHO. (2022). Global Hepatitis Report.
[2] AbbVie. (2022). NAQUIVAL Product Monograph & Regulatory Filings.
[3] MarketWatch. (2023). Hepatitis C Drug Market Analysis.
[4] IQVIA. (2022). Global Hepatitis C Treatment Data.